Substantial Amount of Anticounterfeit Litigation Hit the Courts in Late 2021
April 6, 2022
RPX’s latest quarterly review details in part how operating companies added 1,179 defendants to patent litigation campaigns in 2021, a 7.9% decrease from the prior year. However, these operating company data exclude a distinct category of...
Read full postPTAB Petitions Dipped in Q4 and 2021 as Prior Reforms Drew Further Congressional Focus
March 30, 2022
In the fourth quarter of 2021, 339 petitions for America Invents Act (AIA) review were filed with the Patent Trial and Appeal Board (PTAB), including 323 petitions for inter partes review (IPR) and 16 petitions for post-grant review (PGR). ...
Read full postWest Texas Remained the Top Patent Venue in 2021 as Judge Albright Attracted Further Scrutiny
March 23, 2022
The Western District of Texas was the most popular venue for overall patent litigation and NPE litigation in 2021 as a whole and in the fourth quarter, holding second place for operating company litigation in both periods. Delaware took sec...
Read full postIP Edge Sued Around 50 Defendants Every Month in 2021
March 16, 2022
RPX’s Q4 in Review takes a look back at key NPE litigation trends in 2021 and before—including the behavior of patent monetization firm IP Edge LLC, which has long been one of the top patent litigants by defendants added to litigation c...
Read full postAIA Trial Institution Rates Leveled Out in 2021 Amid Continued Debate over NHK-Fintiv
March 10, 2022
The Patent Trial and Appeal Board (PTAB) instituted trial in 61% of the America Invents Act (AIA) review petitions addressed in the fourth quarter of 2021, bringing the year’s institution rate to 58.7%—slightly higher than 2020’s 58.2...
Read full postNPE Litigation Ticked Up Last Quarter as Operating Company Activity Dipped Further
March 2, 2022
NPEs added 551 defendants to patent litigation campaigns in Q4 2021—up slightly from the same quarter last year though down by around 8% compared to Q3 and beating the trailing fourth-quarter 2018-2020 average by 16.1%. Litigation from fi...
Read full postANDA Litigation Remained Clustered in Historic Hotspots Last Year Despite Narrowed Venue Options
February 23, 2022
In 2021, the vast majority of patent litigation targeting generic drugmakers—i.e., cases alleging infringement through the filing of Abbreviated New Drug Applications (ANDAs)—was filed in Delaware and New Jersey, historically the hotspo...
Read full postWest Texas’s Judge Albright Remains the Nation’s Most Active Patent Judge
February 16, 2022
The top judge for patent litigation in both 2021 and Q4 was District Judge Alan D. Albright, who has played a key role in the Western District of Texas’s rise to the top of the venue charts over the past several years. In 2021, 19% of all...
Read full postIP Edge, 2021’s Top Plaintiff, Has a Long and Litigious History
February 9, 2022
RPX’s Q4 in Review detailed how NPE litigation increased by around 10% in 2021, both with and without the activity of one particularly litigious NPE: the patent monetization firm IP Edge LLC. Entities controlled by IP Edge have collective...
Read full postNPE Litigation Targeting Financial Services Doubled in 2021
February 2, 2022
As recently reported by RPX in its Q4 in Review, NPE litigation targeting the Financial Services sector rose during 2021, with double the number of defendants added to litigation compared to the same period in 2020. Forty-three of those def...
Read full post